Osteosarcoma treatment – Where do we stand? A state of the art review

Raymond, 2009, Osteosarcoma multidisciplinary approach to the management from the pathologist’s perspective, Cancer Treat Res, 152, 63, 10.1007/978-1-4419-0284-9_4 Gorlick, 2009, Current concepts on the molecular biology of osteosarcoma, Cancer Treat Res, 152, 467, 10.1007/978-1-4419-0284-9_27 Bielack, 2009, Casali PG; ESMO guidelines working group. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up, Ann Oncol, 20, 137, 10.1093/annonc/mdp154 Entz-Werle, 2003, Genetic alterations in primary osteosarcoma from 54 children and adolescents by targeted allelotyping, Br J Cancer, 88, 1925, 10.1038/sj.bjc.6600968 Ottaviani, 2010, The epidemiology of osteosarcoma, Cancer Treat Res, 152, 3, 10.1007/978-1-4419-0284-9_1 Geller, 2010, Osteosarcoma: a review of diagnosis, management, and treatment strategies, Clin Adv Hematol Oncol, 8, 705 Kager, 2010, COSS study group. Osteosarcoma in very young children: experience of the Cooperative Osteosarcoma Study Group, Cancer, 116, 5316, 10.1002/cncr.25287 Bielack, 2002, Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols, J Clin Oncol, 20, 776, 10.1200/JCO.20.3.776 Bielack, 2009, Osteosarcoma: the COSS experience, Cancer Treat Res, 152, 289, 10.1007/978-1-4419-0284-9_15 Ozaki, 2002, Osteosarcoma of the spine: experience of the Cooperative Osteosarcoma Study Group, Cancer, 94, 1069, 10.1002/cncr.10258 Clark, 2008, A review of clinical and molecular prognostic factors in osteosarcoma, J Cancer Res Clin Oncol, 134, 281, 10.1007/s00432-007-0330-x Jawad, 2011, Osteosarcoma: improvement in survival limited to high-grade patients only, J Cancer Res Clin Oncol, 137, 597, 10.1007/s00432-010-0923-7 Ozaki, 2003, Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group, J Clin Oncol, 21, 334, 10.1200/JCO.2003.01.142 Ta, 2009, Osteosarcoma treatment: state of the art, Cancer Metastasis Rev, 28, 247, 10.1007/s10555-009-9186-7 Schwab, 2012, Osteosarcoma of the mobile spine, Spine (Phila Pa 1976), 37, E381, 10.1097/BRS.0b013e31822fb1a7 Isakoff, 2012, Poor survival for osteosarcoma of the pelvis: a report from the children’s oncology group, Clin Orthop Relat Res, 470, 2007, 10.1007/s11999-012-2284-9 Chou, 2008, Therapy for osteosarcoma: where do we go from here?, Paediatr Drugs, 10, 315, 10.2165/00148581-200810050-00005 Bacci, 2006, Bone metastases in osteosarcoma patients treated with neoadjuvant or adjuvant chemotherapy: the Rizzoli experience in 52 patients, Acta Orthop, 77, 938, 10.1080/17453670610013268 Kager, 2003, Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols, J Clin Oncol, 21, 2011, 10.1200/JCO.2003.08.132 Carrle, 2009, Osteosarcoma lung metastases detection and principles of multimodal therapy, Cancer Treat Res, 152, 165, 10.1007/978-1-4419-0284-9_8 Bacci, 2003, Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide, Ann Oncol, 14, 1126, 10.1093/annonc/mdg286 Kempf-Bielack, 2005, Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS), J Clin Oncol, 23, 559, 10.1200/JCO.2005.04.063 Errani, 2011, Palliative therapy for osteosarcoma, Expert Rev Anticancer Ther, 11, 217, 10.1586/era.10.172 Bacci, 2008, High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions, J Surg Oncol, 98, 415, 10.1002/jso.21140 Ferrari, 2003, Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival, J Clin Oncol, 21, 710, 10.1200/JCO.2003.03.141 Hauben, 2006, Clinico-histologic parameters of osteosarcoma patients with late relapse, Eur J Cancer, 42, 460, 10.1016/j.ejca.2005.09.032 Franke, 2011, Solitary skeletal osteosarcoma recurrence. Findings from the Cooperative Osteosarcoma Study Group, Pediatr Blood Cancer, 56, 771, 10.1002/pbc.22864 Grimer, 2002, Cannon SR; surgical subcommitte of the European Osteosarcoma Intergroup. Surgical outcomes in osteosarcoma, J Bone Joint Surg Br, 84, 395, 10.1302/0301-620X.84B3.12019 Sajadi, 2004, The incidence and prognosis of osteosarcoma skip metastases, Clin Orthop Relat Res, 426, 92, 10.1097/01.blo.0000141493.52166.69 Kager, 2006, Cooperative Osteosarcoma Study Group. Skip metastases in osteosarcoma: experience of the Cooperative Osteosarcoma Study Group, J Clin Oncol, 24, 1535, 10.1200/JCO.2005.04.2978 Bielack, 2009, Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive Cooperative Osteosarcoma Study Group patients, J Clin Oncol, 27, 557, 10.1200/JCO.2008.16.2305 Schwarz, 2009, The role of radiotherapy in oseosarcoma, Cancer Treat Res, 152, 147, 10.1007/978-1-4419-0284-9_7 Yasko, 2009, Surgical management of primary osteosarcoma, Cancer Treat Res, 152, 125, 10.1007/978-1-4419-0284-9_6 Jaffe, 2009, Osteosarcoma: review of the past, impact on the future. The American experience, Cancer Treat Res, 152, 239, 10.1007/978-1-4419-0284-9_12 Marulanda, 2008, Orthopedic surgery options for the treatment of primary osteosarcoma, Cancer Contr, 15, 13, 10.1177/107327480801500103 Andreou, 2011, The influence of tumor- and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols, Ann Oncol, 22, 1228, 10.1093/annonc/mdq589 Hattinger, 2010, Emerging drugs for high-grade osteosarcoma, Expert Opin Emerg Drugs, 15, 615, 10.1517/14728214.2010.505603 Carrle, 2006, Current strategies of chemotherapy in osteosarcoma, Int Orthop, 30, 445, 10.1007/s00264-006-0192-x Smeland, 2011, Results of the scandinavian sarcoma group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years, Acta Orthop, 82, 211, 10.3109/17453674.2011.566141 DeLaney, 2005, Radiotherapy for local control of osteosarcoma, Int J Radiat Oncol Biol Phys, 61, 492, 10.1016/j.ijrobp.2004.05.051 Mahajan, 2008, Multimodality treatment of osteosarcoma: radiation in a high-risk cohort, Pediatr Blood Cancer, 50, 976, 10.1002/pbc.21451 Machak, 2003, Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities, Mayo Clin Proc, 78, 147, 10.4065/78.2.147 Ciernik, 2011, Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma, Cancer, 117, 4522, 10.1002/cncr.26037 Berger, 2012, 153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients, Ann Oncol, 23, 1899, 10.1093/annonc/mdr542 Whelan, 2006, Management of osteosarcoma, Curr Treat Options Oncol, 7, 444, 10.1007/s11864-006-0020-y Longhi, 2006, Primary bone osteosarcoma in the pediatric age: state of the art, Cancer Treat Rev, 32, 423, 10.1016/j.ctrv.2006.05.005 Waters, 1979, Treatment of osteosarcoma, Clin Exp Pharmacol Physiol, 5, 11 Meyers, 1992, Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience, J Clin Oncol, 10, 5, 10.1200/JCO.1992.10.1.5 Link, 1991, Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the multi-institutional osteosarcoma study, Clin Orthop Relat Res, 270, 8, 10.1097/00003086-199109000-00003 Goorin, 2003, Pediatric Oncology Group. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: pediatric oncology group study POG-8651, J Clin Oncol, 21, 1574, 10.1200/JCO.2003.08.165 Janeway, 2010, Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects, Lancet Oncol, 11, 670, 10.1016/S1470-2045(10)70062-0 Marina, 2009, International collaboration is feasible in trials for rare conditions: the EURAMOS experience, Cancer Treat Res, 152, 339, 10.1007/978-1-4419-0284-9_18 Daw, 2011, Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children’s Research Hospital OS99 trial, Cancer, 117, 2770, 10.1002/cncr.25715 Ferrari, 2009, The treatment of nonmetastatic high grade osteosarcoma of the extremity: review of the Italian Rizzoli experience. Impact on the future, Cancer Treat Res, 152, 275, 10.1007/978-1-4419-0284-9_14 Anninga, 2011, Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?, Eur J Cancer, 47, 2431, 10.1016/j.ejca.2011.05.030 Fuchs, 1998, Long-term results of the co-operative German–Austrian–Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs, Ann Oncol, 9, 893, 10.1023/A:1008391103132 Winkler, 1990, Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86), Cancer, 66, 1703, 10.1002/1097-0142(19901015)66:8<1703::AID-CNCR2820660809>3.0.CO;2-V Imran, 2009, Effect of time to resumption of chemotherapy after definitive surgery on prognosis for non-metastatic osteosarcoma, J Bone Joint Surg Am, 91, 604, 10.2106/JBJS.H.00449 Eselgrim, 2006, Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials, Pediatr Blood Cancer, 47, 42, 10.1002/pbc.20608 Nagarajan, 2011, Twenty years of follow-up of survivors of childhood osteosarcoma: a report from the Childhood Cancer Survivor Study, Cancer, 117, 625, 10.1002/cncr.25446 Gelderblom, 2011, European Osteosarcoma Intergroup. Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials, Eur J Cancer, 47, 895, 10.1016/j.ejca.2010.11.036 Saeter, 1995, Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival, Cancer, 75, 1084, 10.1002/1097-0142(19950301)75:5<1084::AID-CNCR2820750506>3.0.CO;2-F Muñoz, 2009, Long-term results of the Spanish protocol SO-95 for the treatment of non-metastatic high-grade osteosarcoma of the extremities in children, Clin Transl Oncol, 11, 387, 10.1007/s12094-009-0373-3 Widemann, 2004, High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma, Cancer, 100, 2222, 10.1002/cncr.20255 Ferrari, 2009, Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma, J Chemother, 21, 205, 10.1179/joc.2009.21.2.205 Bacci, 2006, Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy, J Pediatr Hematol Oncol, 28, 774, 10.1097/01.mph.0000243664.02174.73 Hauben, 2003, Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma, Eur J Hum Genet, 11, 611, 10.1038/sj.ejhg.5201012 Aung, 2002, Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering cancer center experience, Cancer, 95, 1728, 10.1002/cncr.10861 Chou, 2006, Chemotherapy resistance in osteosarcoma: current challenges and future directions, Expert Rev Anticancer Ther, 6, 1075, 10.1586/14737140.6.7.1075 Huang, 2012, HMGB1 promotes drug resistance in osteosarcoma, Cancer Res, 72, 230, 10.1158/0008-5472.CAN-11-2001 Meyers, 2008, Children’s oncology group. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival – a report from the children’s oncology group, J Clin Oncol, 26, 633, 10.1200/JCO.2008.14.0095 Bielack, 2008, Osteosarcoma: the same old drugs or more?, J Clin Oncol, 26, 3102, 10.1200/JCO.2008.17.1108 Hunsberger, 2008, Complexities in interpretation of osteosarcoma clinical trial results, J Clin Oncol, 26, 3103, 10.1200/JCO.2008.17.3484 Saeter, 1991, Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a scandinavian sarcoma group study, J Clin Oncol, 9, 1766, 10.1200/JCO.1991.9.10.1766 Smeland, 2003, SSGVIII study: prognostic factors for outcome and role of replacement salvage chemotherapy for poor histologic responders, Eur J Cancer, 39, 488, 10.1016/S0959-8049(02)00747-5 Bruland, 2009, Treatment of osteosarcoma. The scandinavian sarcoma group experience, Cancer Treat Res, 152, 309, 10.1007/978-1-4419-0284-9_16 Bacci, 2000, Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico Rizzoli according to the IOR/OS2 protocol: an update report, J Clin Oncol, 18, 4016, 10.1200/JCO.2000.18.24.4016 Bacci, 2001, Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli’s 4th protocol, Eur J Cancer, 37, 2030, 10.1016/S0959-8049(01)00229-5 Ferrari, 2005, J Clin Oncol, 23, 8845, 10.1200/JCO.2004.00.5785 Picci, 2010, Survival in high-grade osteosarcoma: improvement over 21 years at a single institution, Ann Oncol, 21, 1366, 10.1093/annonc/mdp502 Le Deley, 2007, SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients, Eur J Cancer, 43, 752, 10.1016/j.ejca.2006.10.023 Bramwell, 1992, A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European osteosarcoma intergroup, J Clin Oncol, 10, 1579, 10.1200/JCO.1992.10.10.1579 Souhami, 1997, Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European osteosarcoma intergroup, Lancet, 350, 911, 10.1016/S0140-6736(97)02307-6 Lewis, 2007, J Natl Cancer Inst, 99, 112, 10.1093/jnci/djk015 EURAMOS. www.ctu.mrc.ac.uk/euramos. Accessed 10 March 2012. Ref type: electronic citation Whelan, 2012, Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Ontergroup randomised controlled trials, Ann Oncol, 23, 1607, 10.1093/annonc/mdr491 Pakos, 2009, Prognostic factors and outcomes for osteosarcoma: an international collaboration, Eur J Cancer, 45, 2367, 10.1016/j.ejca.2009.03.005 Bacci, 2006, Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution, Cancer, 106, 1154, 10.1002/cncr.21724 Janeway, 2012, Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children’s Oncology Group, Cancer, 118, 4597, 10.1002/cncr.27414 Grimer, 2003, Osteosarcoma over the age of forty, Eur J Cancer, 39, 157, 10.1016/S0959-8049(02)00478-1 Meyers, 1998, Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol, J Clin Oncol, 16, 2452, 10.1200/JCO.1998.16.7.2452 Li, 2012, Impact of close surgical margin on local recurrence and survival in osteosarcoma, Int Orthop, 36, 131, 10.1007/s00264-011-1230-x Choy, 2012, High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes, Cancer, 118, 2905, 10.1002/cncr.26617 van Oosterwijk, 2013, Update on targets and novel treatment options for high-grade osteosarcoma and chondrosarcoma, Hematol Oncol Clin North Am, 27, 1021, 10.1016/j.hoc.2013.07.012 Grignani, 2012, A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group Study, Ann Oncol, 23, 508, 10.1093/annonc/mdr151 Anderson, 2013, Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments, Pediatr Blood Cancer